Dr. Iseult Browne, a clinical research fellow at the ICR and first author of the study, said: “Our study shows that a simple ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...
A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP ...
A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...
Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
Drs. Gulden Menderes and Levent Mutlu, gynecological oncologists with Health First Medical Group, stress to women to speak up.
Fast Track designation granted by U.S. FDA for evaluation of ETX-19477 in patients with BRCA-mutated, platinum-resistant ...
DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...
BUFFALO GROVE, Ill., Dec. 19, 2025 /PRNewswire/ -- Tolmar, Inc. (Tolmar) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Rubraca® (rucaparib), ...
Rubraca is now FDA-approved for BRCA mutation-associated mCRPC after prior androgen receptor-directed therapy, confirming its efficacy in the TRITON3 trial. The TRITON3 trial showed Rubraca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback